Prof. Dr. Thorsten Langer is a Paediatric Oncologist. He is involved in running interdisciplinary late effects clinics for survivors of cancer during childhood, adolescence and young adulthood, and linking these to national and international late effects clinics. He is member of I-BFM-SG ELTEC since 1995, study chairman of “late effects” since 2008 in Germany, and has participated in national and international studies on late effects, in particular, genetic causes of cardio- and ototoxicity.
Thorsten leads the multi-country implementation study of the SurPass in Germany.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 899999. The material presented and views expressed here are the responsibilities of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.